Global Bivalirudin and Desmopressin Market Size, Forecast, and Trend Highlights Over 2022

Table of Content Download Free Sample Now

Report ID: 266 | Published On: Jan 16, 2023

Preview Analysis

Request Insights

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.

In The News

A definitive agreement has been signed between Pfizer Inc. and Global Blood Therapeutics, Inc. Pfizer Inc. will acquire GBT, a biopharmaceutical company devoted to discovering and developing life-changing treatments for isolated patient groups.
AmbioPharm Inc., a leader in CDMO services for peptide APIs, announced the opening of its Shanghai campus and the appointment of members of its European executive team.

Global Bivalirudin and Desmopressin Market Size, Forecast, and Trend Highlights Over 2022 - 2031

Key Questions Answered in the Report

1) What are the major factors driving the growth of the bivalirudin and desmopressin market?

Ans: Rising prevalence of cardiovascular diseases along with increasing number of elderly people suffering from nocturia are the major factors driving the growth of the bivalirudin and desmopressin market.

2) What would be the CAGR of bivalirudin and desmopressin market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2031.

3) What are the challenges affecting the bivalirudin and desmopressin market growth?

Ans: High cost associated with the bivalirudin drug along with the health concerns such as bleeding, difficulty breathing, and sudden numbness are challenges expected to hinder market growth.

4) Which region will provide more business opportunities for growth of bivalirudin and desmopressin market in future?

Ans: The market in North America is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.

5) Who are the major players dominating the bivalirudin and desmopressin market?

Ans: The major players in the market are Pfizer, Inc., Hainan Shuangcheng Pharmaceuticals Co. Ltd., AmbioPharm Inc., Abott India Limited, The Medicines Company, Sun Pharmaceuticals Industries Limited, Ferring Pharmaceuticals, and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the bivalirudin and desmopressin market?

Ans: The market is segmented by application, end user, and by region.

8) Which segment captures the largest market size in application segment in the bivalirudin and desmopressin market?

Ans: The percutaneous coronary intervention (PCI) procedures segment is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.

Healthcare & Pharmaceutical